How long do you take targeted drugs for lung cancer?
The time taken for targeted treatment of lung cancer needed to be considered from both the patient's own condition and the progression of the disease. For patients with middle-stage lung cancer, it is recommended to take the first-generation targeted drug for 1.5 - 2 years or the third-generation targeted drug for 3 years. For patients with advanced lung cancer, as long as the targeted drug was effective, it was recommended to take it until the disease progressed. If drug resistance appeared, the targeted drug would need to be replaced. However, it should be noted that the premise of using targeted drugs was that the patient must have a clear target for treatment in the body, and there must be a specific drug targeting the target before targeted drug therapy could be carried out. Less than 20% of lung cancer patients could find targeted drugs. Read more exciting novels for free
How long will it take for targeted drugs to be effective for lung cancer?
Patients with lung cancer usually took targeted drugs for ten days, no more than forty days, and the effect would take effect in two to three days. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it always effective to take targeted drugs for lung cancer?
The effect of targeted drugs on lung cancer patients was not very good. Target drugs could not cure lung cancer. Although they could prolong survival time, they could not always be effective. There were very few driver mutations in lung cancer, so there were relatively few targeted drugs that could be used. When using targeted drugs, it was necessary to find the target of lung cancer and could not be used blindly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it useful to take targeted drugs for esophagus cancer metastasizing?
At present, a variety of targeted drugs were available for the treatment of esophagus cancer, including new small molecules multi-target Tyrosin Kinase Inhibition, drugs that targeted HEL2, cetuxed that targeted the egFr target, and bevacizumb that targeted the veg-like growth factor target, etc. There was also a combination of PD1 - 1 inhibition and targeted HEL2 for the treatment of cancer at the gastric-esophagus junction. Chinese studies have shown that as a new small-molecular multi-target Tyrosinase Kinase Inhibition, anlotinib and apitini have a certain effect in the treatment of esophagus cancer. The combination therapy of trastuzumab-targeted to HEL2 and PD1 inhibition drugs (such as pembrolizumab) combined with chemotherapy can be used as the first-line treatment for cancer of the gastroesophagus junction, advanced gastric cancer with HEL2 positive, and esophagus cancer. In the second-line treatment of China guidelines for the treatment of esophagus cancer, level II recommendations were given to anlotinib (Class 2A) and apitini (Class 3). However, there were no phase III clinical trials to prove that molecular targeted drugs could prolong the survival of patients with esophagus cancer. The effect of targeted therapy needed further study. In general, molecular targeted therapy had a certain clinical value for the treatment of patients with esophagus cancer, including those with metastasizing, but it still needed further in-depth research. These drugs must be used under the guidance of a professional doctor. It is not recommended for patients to buy and take them themselves to avoid serious adverse reactions. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of breast cancer targeted drugs
There were mainly the following types of breast cancer targeted drugs: 1. Anti-neoplastic targeted drugs: There are intravenous preparations and oral drugs, but the effect in the treatment of breast cancer is not ideal. For example, bevacidol (Avastin) will be considered in some cases. 2. Anti-Her- 2 targeted drugs: targeted at HER - 2 positive patients, it is the most important targeted drug for breast cancer, mainly including trastuzumab (Herceptin), pertubizab, dm- 1, lapatini, etc. The prerequisite for use was that the patient was positive for HER - 2 (+++ in the immune tissue test). If the immune tissue test was ++, the patient would need to undergo a further FISH test. The patient could only be used if the FISH test was positive. If the immune tissue test was + or-, the patient could not be used. 3. A targeted drug for patients with fetal mutations in the Brca lineage: The main drug is olaparib, which is used to treat patients with metastasizing breast cancer who have harmful or suspected harmful mutations in the Brca lineage and who are negative for the human embryonic growth factor receptor 2 (HEL2). 4. Immune therapy (in a sense, it was also a targeted drug): Anti-PD- 1/PD-L1 Monoclone Antibodies, which essentially relieved immune suppression and activated immune cells to kill cancer cells. 5. mTO inhibition drugs, such as everolimus and sirolimus, can inhibit the activation of the mTO signaling pathway, thereby suppressing the growth and metabolism of tumor cells. 6. Other targeted therapy drugs, such as Parp inhibition drugs, CD 4/6 inhibition drugs, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Take the third generation of targeted drugs after the first generation of targeted drugs are resistant
After the first-generation targeted drug became resistant, the third-generation targeted drug could be considered. According to the data in document [2], after the first-generation targeted drug became resistant, only about 25% of patients had the opportunity to use osimertinib for second-line treatment. According to the study mentioned in document [4], the first-line use of osimertinib for the treatment of egfr-positive lung cancer, followed by comprehensive treatment methods such as chemotherapy and chemotherapy after drug resistance, the patient's overall survival time was 41.4 months, which was twice as long as the first-generation targeted drug. In addition, the document [5] mentioned the dual-target combination therapy plan, specifically the first-line treatment of the third-generation TKi osimertinib combined with the first-generation TKi gefitini, with a disease control rate of 100%. Therefore, for patients who were resistant to first-generation targeted drugs, third-generation targeted drugs might be an effective treatment option.
Is it useful to take targeted drugs after chemotherapy and discharge? How long?
Compared with traditional chemotherapy drugs, anti-tumor targeted drugs had a completely different mechanism of action. At the same time, they had the significant advantages of high efficiency, low toxicity, and strong specialization. It was useful to use targeted drugs after discharge from chemotherapy, but the specific duration of effect would be affected by many factors. The drug resistance of targeted drugs was an important factor that affected their duration of action. Cancer cells would mutate. Although targeted drugs could accurately attack cancer cells, they could not identify all cancer cells in all directions. It was easy for drug resistance to occur. When cancer cells develop drug resistance, the effect of the targeted drug will decrease, and at this time, the drug may need to be changed. In order to detect drug resistance problems in time, regular assessment tests, such as tissue examination and blood test, were needed to adjust the medication in time. The individual differences between different patients would also affect the duration of the targeted drug. For cancer patients with specific gene mutations, such as cancer patients with egf-mutation, the targeted drug treatment effect would be more prominent, and the drug efficiency could reach 70%. Before targeted therapy, a comprehensive assessment was needed to understand whether there were specific changes in the genes. Patients who met the conditions would have a better effect if they used targeted drugs. In addition, the way the targeted drug was taken would also affect its effect and duration of effect. For example, the drug should be administered at the same time every day. This would allow the targeted drug to release a stable concentration of the drug, allowing the human body to absorb the drug's effects more deeply. If the timing of taking the medicine was messed up, the concentration of the medicine could not be released stably, which might affect the treatment effect. In short, taking targeted drugs after hospitalization was useful, but it was difficult to determine how long it would last. It was necessary to consider various factors such as drug resistance, individual differences, and medication methods. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long will it take to cure a mild case of lung cancer?
The treatment time for mild cases varies from person to person, and the treatment time may be between six months to two years. For patients with non-drug-resistant primary treatment, the treatment time was usually about six months. However, for patients with chronic underlying diseases, the treatment time may need to be extended to nine months. If it was a re-treated mild form of lung cancer or a drug-resistant strain, treatment usually took 1-2 years. Therefore, the treatment time for mild lung cancer needed to be determined according to the patient's specific condition.
What are the drugs for lung cancer bone marrow suppression?
For lung cancer bone marrow suppression, there are the following related drugs: 1. ** Granule-colony stimulating factor (G-CHF)**: Commonly used for the treatment of grade III-IV bone marrow suppression. It can be used continuously until the absolute number of neutrons returns to the normal range for two consecutive times. 2. ** Likejun, shark liver alcohol, Shengbai capsules, etc. **: When the number of white blood cells decreased after chemotherapy and the bone marrow suppression was grade I-II, these oral white blood increasing drugs could be the first choice. 3. ** Red blood cell stimulating hormone (rhEP)**: It is suitable for patients who are anemia-induced after chemotherapy, have impaired kidney function, or have concerns about transfusion-related risks. The drug should be stopped when the hemoglobin-level is greater than 100g/L. 4. ** rhIL11 **: For patients who have suffered from Platelet Decay after chemotherapy and do not meet the indication for Platelet Transfusion (25 - 75) ×10 ng/L, it can be injected once a day for 7 - 14 days until the bone marrow suppression effect disappears or the drug withdrawal criteria are met. The drug should be stopped 48 hours before the start of the next chemotherapy. 5. ** Trasil **: A type of CD 4/6 inhibition drug that can fully protect the bone marrow's hemopotential during chemotherapy. It can significantly reduce the occurrence of bone marrow suppression events and improve the safety and anti-tumor efficacy of chemotherapy. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long does the targeted drug for gastric cancer usually take effect?
The treatment of targeted drugs for gastric cancer generally took about three months to observe the effect. During the treatment process, the patient's physiological and biochemical indicators needed to be tested regularly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the good targeted drugs for brain metastasizing from esophagus cancer?
The targeted drugs that could be used for brain metastasizing of esophagus cancer included: human embryonic growth factor receptor pepsinase inhibition agents, gefitini, erlotinib, cetuxed, which inhibited neoplasia, and bevacidation combined with chemotherapy drugs, which could significantly improve survival rates. Anti-neoplasia drugs, such as bevacidation, ramoisurab, etc., were more effective through targeted therapy combined with chemotherapy. However, it should be noted that the targeted drugs for esophagus cancer were still in the clinical research stage. They had not been included in the guidelines for routine clinical use, and they needed to be used under the guidance of doctors. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>